Skip to main content
Premium Trial:

Request an Annual Quote

Microbiome Research Firm Biohm Raises $7.5M in Private Round

NEW YORK — Microbiome research firm Biohm said on Thursday that it has raised $7.5 million in an oversubscribed financing round.

The round was led by VTC Ventures with participation from Felton Group, Jobs Ohio Growth Capital Fund, Aztec Capital Management, Cleveland Life Science Advisors, Valley Growth Ventures, and Jump Start, among other investors.

Biohm offers a range of direct-to-consumer products including probiotic supplements and a test kit for analyzing bacterial and fungal DNA in self-collected fecal samples. The Cleveland, Ohio-based firm also partners with other businesses to use its microbiome data and bioinformatics technology and expertise in product development.

In early 2018, Biohm also kicked off a study investigating the link between autism and the gut microbiome.

"This raise will allow us to further develop our [artificial intelligence] technologies, removing the guess work in our targeted formulation process," Biohm President Sam Schatz said in a statement.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.